{"filing":{"accession_number":"0001140361-26-034735","cik":"0001635088","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"ef20081229_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/ef20081229_8k.htm"},"events":[{"id":30123,"run_id":27606,"accession_number":"0001140361-26-034735","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA approval of LISRAYA (brepocitinib) for dermatomyositis treatment, a significant regulatory and commercial milestone for Roivant's subsidiary Priovant. While this is a material operational event affecting the company's product portfolio and market position, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M\u0026A activity, or material litigation). The approval represents a major product launch and regulatory achievement that would materially affect a reasonable investor's assessment of the company's pipeline and commercial prospects.","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32633,"accession_number":"0001140361-26-034735","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of LISRAYA (brepocitinib) for dermatomyositis treatment, a significant regulatory and commercial milestone for Roivant's subsidiary Priovant. While this is a material operational event affecting the company's product portfolio and market position, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M\u0026A activity, or material litigation). The approval represents a major product launch and regulatory achievement that would materially affect a reasonable investor's assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T21:25:46.418047+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32633,"accession_number":"0001140361-26-034735","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of LISRAYA (brepocitinib) for dermatomyositis treatment, a significant regulatory and commercial milestone for Roivant's subsidiary Priovant. While this is a material operational event affecting the company's product portfolio and market position, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M\u0026A activity, or material litigation). The approval represents a major product launch and regulatory achievement that would materially affect a reasonable investor's assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T21:25:46.418047+00:00","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-08-27"}]}